Topics

Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 16, Status: Authori

09:32 EDT 3 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 16, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 16, Status: Authori

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 16, Status: Authori"

Quick Search

Relevant Topic

Joint Disorders
A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint causes pain, stiffness, and swelling with ...